Prostaglandins, masculinization and its disorders

Citation for published version:

Digital Object Identifier (DOI):
10.1371/journal.pone.0062556

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
PLoS ONE

Publisher Rights Statement:
Copyright: © 2013 Dean et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Prostaglandins, Masculinization and Its Disorders: Effects of Fetal Exposure of the Rat to the Cyclooxygenase Inhibitor- Indomethacin

Afshan Dean, William Mungall, Chris McKinnell, Richard M. Sharpe

MRC Centre for Reproductive Health, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, Scotland, United Kingdom

Abstract

Recent studies have established that masculinization of the male reproductive tract is programmed by androgens in a critical fetal ‘masculinization programming window’ (MPW). What is peculiar to androgen action during this period is, however, unknown. Studies from 20 years ago in mice implicated prostaglandin (PG)-mediation of androgen-induced masculinization, but this has never been followed up. We therefore investigated if PGs might mediate androgen effects in the MPW by exposing pregnant rats to indomethacin (which blocks PG production by inhibiting cyclooxygenase activity) during this period and then examining if androgen production or action (masculinization) was affected. Pregnant rats were treated with indomethacin (0.8 mg/kg/day; e15.5–e18.5) to encompass the MPW. Indomethacin exposure decreased fetal bodyweight (e21.5), testis weight (e21.5) and testicular PGE2 (e17.5, e21.5), but had no effect on intratesticular testosterone (ITT; e17.5) or anogenital index (AGI; e21.5). Postnatally, AGI, testis weight and blood testosterone were unaffected by indomethacin exposure and no cryptorchidism or hypospadias occurred. Penis length was normal in indomethacin-exposed animals at Pnd25 but was reduced by 26% (p<0.001) in adulthood, an effect that is unexplained. Our results demonstrate that indomethacin can effectively decrease intra-testicular PGE2 level. However, the resulting male phenotype does not support a role for PGs in mediating androgen-induced masculinization during the MPW in rats. The contrast with previous mouse studies is unexplained but may reflect a species difference.

Introduction

Masculinization by androgens is a pivotal event in the development of a phenotypic male, and mild disorders of this process (hypospadias, cryptorchidism) are common in human males at birth [1–3]. In rats, there is a critical period, the masculinization programming window (MPW), during which sufficient testosterone, produced by the fetal testis, ‘programs’ the male reproductive tract so that it can differentiate and grow normally after the MPW [4]. Any impairment of androgen action during the MPW results in smaller reproductive organs and/or abnormal function as well as decreased anogenital distance (AGD) [4],[5]. AGD, the distance between the anus and genitalia, is about twice as long in male rats as in females and provides a life-long readout of androgen action during the MPW [4]. A similar MPW may exist in humans, within the period 8–14 weeks of gestation [4], and AGD is approximately twice as long in males as in females at birth [6],[7] and is therefore suggested to provide a similar read-out of fetal androgen exposure in the MPW as in the rat [6–9].

The molecular mechanisms and androgen pathways triggered during the MPW remain to be elucidated. Prostaglandins (PGs) are potentially implicated based on early studies by Gupta [10],[11] in which treatment of pregnant mice with cyclooxygenase (COX) inhibitors (aspirin, indomethacin) during the period of the MPW was shown to reduce male AGD, with the effect clearly downstream of androgen action. PGs are lipid compounds derived from arachidonic acid [12]. They mediate many important biological functions, acting in a paracrine or autocrine fashion. COX1 and COX2 are fundamental enzymes in the synthesis of PGs from arachidonic acid. PGs are recognized to be involved in various reproductive functions such as ovulation and implantation [13],[14] and induction of labor [15],[16].

There is further evidence supporting a role for PGs in mediating aspects of androgen action in the MPW. Four epidemiological studies have shown that use of paracetamol (acetaminophen), with/without other painkillers that interfere with PG production (such as aspirin), by women in pregnancy during the period of the proposed MPW, significantly increase the risk of cryptorchidism in sons [17–20]. Rat studies have shown that inhibition of androgen action in the MPW increases incidence of cryptorchidism [4],[21] and, consistent with this, paracetamol and/or other prostaglandin inhibitors (aspirin, indomethacin) have been shown to reduce testosterone production in vitro by fetal rat testes [22]. Viewed together, the aforementioned data makes a strong case for the possibility that prostaglandins mediate aspects of androgen action in the MPW, and with human health relevance. The objective of the present study was to directly test this possibility by investigating in the rat if inhibition of PG production by indomethacin during...
the MPW was able to interfere with normal masculinization and thus to induce male reproductive disorders such as hypospadias or cryptorchidism. These disorders are associated with a decrease in androgen action during the MPW resulting in a decreased AGD [4].

Methods

Animals and Treatments
For all studies, animals were treated humanely and with regard for alleviation of suffering. Studies were performed according to the Animal (Scientific Procedures) Act 1986 following specific approval by the UK Home Office. Studies were conducted under Project Licence PPL 60/3914 following review by the University of Edinburgh Animal Research Ethics Committee. Wistar rats were maintained according to UK home office guidelines and had free access to fresh tap water and soy free diet (SDS; Dundee, Scotland). Time-matings were established by the presence of a vaginal plug and this was defined as embryonic day (e) 0.5. To investigate if exposure to indomethacin can affect fetal masculinization, pregnant animals were exposed to indomethacin (Sigma-Aldrich, UK) during the MPW (e15.5–e18.5) to determine if PGs are involved in androgen programming during this time. Animals that were killed on e17.5 received treatment up until e16.5 whereas those sampled on e21.5 received treatment until e18.5. The indomethacin dose of 0.8 mg/kg was selected following preliminary studies that investigated a number of doses (2, 1 or 0.8 mg/kg) but which determined that the two higher doses resulted in unacceptable litter loss and/or severe maternal intra-gastric bleeding. Control dams were injected with corn oil daily in the same time window (e15.5–e18.5). Data for male offspring collected in fetal life were from a minimum of 6 litters per treatment group and for postnatal studies from a minimum of 3 litters.

Tissue recovery and measurements
Control and treated rat dams were killed on either e17.5 (during the MPW), e21.5 or allowed to give birth, and resulting offspring then killed on either postnatal day (Pnd) 25 (= early puberty) or 75 (= adults). For fetal studies, pregnant dams were killed by inhalation of CO2 followed by cervical dislocation, fetuses were removed, and placed in ice-cold PBS (Sigma-Aldrich). E21.5 fetuses were weighed and AGD measured using digital calipers (Faithfull Tools, Kent, UK) and the fetuses then decapitated. The gonads were removed by microdissection from both e15.5 and e21.5 fetuses. Tissue was either stored at −80°C for PGE2 or intratesticular testosterone ELISA assays or fixed in Bouin’s fixative for 1 h, then transferred to 70% (v/v) ethanol and embedded in paraffin wax as above.

Prostaglandin E2 (PGE2) measurement
PGE2 was measured in the fetal gonads from control and indomethacin-treated groups to determine if effective exposure of the fetus had occurred. For collection of e17.5 samples treatment protocol described above was followed, whereby dams were treated on e15.5, e16.5 and e17.5 but then pups were removed 4 h after maternal injection on e17.5, gonads dissected and frozen at −80°C. Although this showed significant suppression by indomethacin of testicular PGE2 levels on e17.5 (ie during the MPW), to provide further reassurance that effective exposure of the fetus was occurring we undertook a similar study outside of the MPW on e21.5. For this study, dams were treated with indomethacin only on e20.5 and e21.5 and culled 4 h after the final treatment (see Fig. S1). Gonads from each animal were pooled and homogenized in 0.05 mM Tris/HCL PH 7.4 and PGE2 levels were determined in each sample using Detect X Prostaglandin E2 Enzyme Immunoassay kit, according to manufacturer’s instructions (Arbor Assays, Michigan, US). PGE2 levels were read using an optical microplate reader (Labsystems, MultiSKan Ex, UK) and results analyzed using MasterPlex™ ReaderFit software (MiraBio Group, Hitachi Ltd).

Testosterone measurements
Fetal intratesticular testosterone levels were measured by competitive radioimmunoassay (RIA). All other details were as described previously [24]. Pnd25 and Pnd75 plasma levels of testosterone were measured using an enzyme-linked immunosorbent assay adapted from an earlier RIA method. This has been described in detail previously [25].

Statistics
Data are expressed as means ±SEM. All analyses used GraphPad Prism. Rat data was analyzed using one-way ANOVA followed by the Bonferroni post-test or using students t-test as appropriate (version 3; GraphPad Software Inc., San Diego, CA, USA). The presented rat data used each animal as the unit rather than the litter, but re-analysis of the data using litter means did not alter any of the main findings. As there were significant treatment effects on bodyweight that may affect AGD, the latter was divided by the cube root of bodyweight to determine the anogenital index (AGI), and this was used in graphs and for statistical analyses. Data for testosterone was log-transformed prior to analysis to remove heterogeneity of variance.

Results

Fetal effects of exposure to indomethacin
At 4 h after maternal indomethacin treatment, PGE2 levels in the fetal testis were significantly decreased at e17.5 (during the MPW) when compared to controls (Fig. 1A), indicating effective exposure of the fetus. To provide further reassurance on this, we established separately that our indomethacin treatment protocol suppressed PGE2 levels in the fetal testis on e21.5 (Fig S1). However, fetal exposure to indomethacin during the MPW did not significantly alter intratesticular testosterone (ITT) levels at e17.5, in comparison to vehicle exposed animals (Fig 1B). Testosterone levels/androgen action during the MPW is reflected in AGD/AGI measurements from e21.5 onwards [4],[5]. In keeping with the data for e17.5 ITT, fetal indomethacin exposure during the MPW did not affect AGI at e21.5 (Fig 2A), but did decrease fetal body weight of e21.5 male fetuses (Fig 2B). Furthermore, exposure to indomethacin caused a significant decrease (27%) in fetal testis weight at e21.5 and this decrease occurred despite the fact that indomethacin treatment had ceased after e18.5 (Fig 2C). If indomethacin treatment (0.8 mg/kg/day) was administered for a longer period (e15.5–e20.5), a similar decrease was found in testis weight (data not shown).
Postnatal effects of fetal exposure to indomethacin

Offspring were evaluated on Pnd25 and Pnd75. In utero exposure to indomethacin did not result in hypospadias or cryptorchidism in any offspring (for vehicle N = 0/56; for indomethacin 0/26).

By puberty (Pnd25), indomethacin exposed males were significantly heavier than vehicle exposed control animals, and this difference was still evident at Pnd75 (Fig. 3A). AGI at Pnd25 and Pnd75 was unaffected by fetal exposure to indomethacin (Fig. 3B) and in utero exposure to indomethacin did not significantly alter plasma levels of testosterone at either age (Fig. 4).

Testis weight in indomethacin-exposed animals was comparable to controls at both ages (Fig. 5A) and there were no gross morphological changes in the testis (data not shown). No change was found in penile length at Pnd25 in indomethacin exposed animals but, unexpectedly, in adulthood, males exposed in utero to indomethacin, had a significantly shorter penile length (26% reduction) than controls (Fig. 5B).

Discussion

Two lines of evidence prompted the present studies. The first was the clear demonstration in mice that exposure to PG inhibitors, such as indomethacin, during the MPW inhibited masculinization (AGD) [10],[11]. The second was evidence from human studies that exposure to acetaminophen (± other painkillers) during the presumptive MPW period increased incidence of cryptorchidism in male offspring [17–20], supported by rat experimental data that treatment with acetaminophen (during the MPW) reduced AGD [19]. A common pathway that might link these findings would be inhibition of PG production, although acetaminophen can also exert effects via other (incompletely understood) mechanisms [26]. We used the rat, in which we have established robust information on timing of the MPW and its susceptibility to disruption [4],[5],[25] to replicate earlier mouse studies [10],[11] and to identify whether interference with PG production/action during the MPW was likely to lead to disorders/impairment of masculinization. Our findings do not support such a role for PGs in the rat.

Despite replicating the treatment protocol of Gupta [10],[11], though with a slightly lower dose of indomethacin (0.8 mg/kg/day), we found no evidence of hypospadias or cryptorchidism in fetal exposure to indomethacin. The body weight was significantly higher in indomethacin exposed males by Pnd25, and this difference was still evident at Pnd75. AGI and AGD were unaffected by fetal exposure to indomethacin. The testis weight was comparable to controls at both ages, and there were no gross morphological changes in the testis (data not shown). In adulthood, males exposed in utero to indomethacin had a significantly shorter penile length than controls.

Figure 1. Effects of maternal exposure to vehicle or indomethacin (0.8 mg/kg/day) on (A) testicular PGE2 levels at e17.5 and (B) intra-testicular testosterone content at e17.5. Values are means ± SEM for N = 5 for the top graph and N = 7–28 for the bottom graph, from a minimum of 3 litters. **p<0.01, in comparison with respective control. doi:10.1371/journal.pone.0062556.g001

Figure 2. Effects of maternal exposure to vehicle or indomethacin (0.8 mg/kg/day; e15.5–e18.5) on anogenital index (A), bodyweight (B) and testis weight (C) at e21.5. Values are means ± SEM for N = 7–45 from a minimum of three litters ***p<0.001 in comparison with respective control. doi:10.1371/journal.pone.0062556.g002
versus 1 mg/kg) because of concerns about confounding maternal toxic effects observed with the higher dose, we were unable to demonstrate any interference with masculinization, in terms of AGD/AGI or reproductive development. One obvious explanation would be that in rats indomethacin did not transfer across the placenta as readily as in mice. We cannot exclude this possibility completely, but our demonstration that indomethacin can decrease PGE2 in the fetal testis 4 h later suggests that placental transfer of indomethacin does occur. The decrease in PGE2 caused by indomethacin exposure during the MPW did not affect ITT levels during the MPW, nor plasma testosterone postnatally nor AGI, suggesting that PGE2 is not crucial for correct and full masculinization in rats. The stark difference in effects of indomethacin in the rat (present studies) and in the mouse [10],[11] is unexplained and is presumed to reflect a species difference. The absence of any effect of indomethacin on ITT in our studies, contrasts with studies in vitro that showed mild inhibition of testosterone production by e14.5 fetal rat testis cultures exposed to 10, but not to 1, micromolar indomethacin for 72 h [22]. This might indicate that higher levels of indomethacin exposure can suppress ITT, but to obtain higher exposure in vivo was not feasible in our rat studies because of maternal toxicity effects.

Some significant effects in males were seen after fetal indomethacin exposure, such as a decrease in testis weight at e21.5, although this corrected postnatally; we are currently investigating the cause of this reduction. One completely unexplained effect of in utero indomethacin exposure was the finding of a significant decrease in adult (final) penile length whereas penis length at Pnd25 was normal. Our previous studies have shown that penis length is programmed by androgen action in the MPW [5],[27],[28], although its growth after this time

![Figure 3. Effects of maternal exposure to vehicle or indomethacin (0.8 mg/kg/day; e15.5–e18.5) on bodyweight (A), and anogenital index (B) at Pnd25 and Pnd75 (adulthood). Values are means ± SEM for N = 6–20 from a minimum of three litters. **p<0.01 in comparison with respective control. doi:10.1371/journal.pone.0062556.g003](image)

![Figure 4. Effects of maternal exposure to vehicle or indomethacin (0.8 mg/kg/day; e15.5–e18.5) on serum testosterone levels at Pnd25 and Pnd75 (adulthood). Values are means ± SEM for N=4–13 animals from a minimum of two litters. doi:10.1371/journal.pone.0062556.g004](image)

![Figure 5. Effects of maternal exposure to vehicle or indomethacin (0.8 mg/kg/day; e15.5–e18.5) on testis weight (A), and penis length (B) at Pnd25 and Pnd75 (adulthood). Values are means ± SEM for N = 6–20 from a minimum of three litters. ***p<0.0001, in comparison with respective control. doi:10.1371/journal.pone.0062556.g005](image)
period is also androgen-dependent [27]. As ITT during the MPW and AGI at all ages was normal in indomethacin-exposed animals, and postnatal blood testosterone levels were normal at the two ages investigated, there is no obvious explanation for this finding. It is possible that fetal indomethacin exposure could have led to transient reduction in gonadotrophin secretion postpubertally, with the resulting lowering of testosterone leading to reduced penile growth, but a mechanism for such a change is not obvious. It should be noted also that, although penis length can vary in adult rats, the average length found in adult indomethacin-exposed animals lay below the range of values that we have seen in controls.

In conclusion, in utero indomethacin exposure did not result in overt inhibition of masculinisation nor the induction of recognisable masculinisation disorders in rats that occur with similar timed exposure to other compounds (e.g. flutamide, dibutyl phthalate) [5,27][29][30]. Although some effects were found, such as a decrease in fetal testis weight and adult penile length, overall masculinisation was unaffected. In summary it can be concluded that exposure to indomethacin during the MPW, at a dose sufficient to cause a decrease in intra-testicular PGE2, is not involved in androgen driven masculinisation during the MPW. More detailed studies as to the role of PGs in penile development are required.

Supporting Information

Figure S1 Effect of maternal exposure to vehicle or indomethacin (0.8 mg/kg/day) on testicular PGE2 levels at e21.5 in rats. Values are means ± SEM for N = 5. *p<0.05, in comparison with respective control. Treatment details are described in Materials & Methods. (TIF)

Author Contributions
Conceived and designed the experiments: AD RMS. Performed the experiments: AD WM CM. Analyzed the data: AD RMS. Wrote the paper: AD RMS.

References